392 related articles for article (PubMed ID: 17192542)
1. Clinical practice. Monoclonal gammopathy of undetermined significance.
Bladé J
N Engl J Med; 2006 Dec; 355(26):2765-70. PubMed ID: 17192542
[No Abstract] [Full Text] [Related]
2. [Monoclonal gammopathies of undetermined significance called "MGUS"].
Clément F
Schweiz Med Wochenschr; 1989 Jul; 119(27-28):970-8. PubMed ID: 2508215
[TBL] [Abstract][Full Text] [Related]
3. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E;
Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884
[No Abstract] [Full Text] [Related]
4. [Current status regarding detection of monoclonal component in Japan].
Yamada T
Rinsho Byori; 2010 Apr; 58(4):397-400. PubMed ID: 20496769
[TBL] [Abstract][Full Text] [Related]
5. [The diagnostic significance of finding a M-component in serum].
Schmidt EB; Møller-Petersen J
Ugeskr Laeger; 1986 Mar; 148(11):633-5. PubMed ID: 3083549
[No Abstract] [Full Text] [Related]
6. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
Kyle RA; Rajkumar SV
Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
[TBL] [Abstract][Full Text] [Related]
7. [Benign monoclonal gammopathy].
Shirota T; Kondo M; Uchida H; Ito H
Nihon Rinsho; 1995 Mar; 53(3):720-4. PubMed ID: 7699912
[TBL] [Abstract][Full Text] [Related]
8. [Monoclonal gammopathy and osteolytic lesions as the initial manifestation of a metastatic hypernephroma].
Castillo Jimeno JM; Illarramendi Mañas JJ; Ruiz Rubio JL; Santiago González A; Sebastián Borruel JL
Arch Esp Urol; 1991 Nov; 44(9):1110-2. PubMed ID: 1807217
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal gammopathy of undetermined significance].
Chaïbi P; Merlin L; Thomas C; Piette F
Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.
Kaplan B; Golderman S; Aizenbud B; Esev K; Kukuy O; Leiba M; Livneh A; Ben-Zvi I
Am J Hematol; 2014 Sep; 89(9):882-8. PubMed ID: 24866208
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal gammopathies of undetermined significance.
Kyle RA; Rajkumar SV
Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
13. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.
Graziani MS; Merlini G
Expert Rev Mol Diagn; 2014 Jan; 14(1):55-66. PubMed ID: 24308339
[TBL] [Abstract][Full Text] [Related]
14. [Determination of lymphocyte subpopulations in multiple myeloma and monoclonal gammopathies of undetermined significance].
Luraschi A; Fedeli P; Rossi M; Montanara S; Perlasca S; Cozzi S
Minerva Med; 1986 Jun; 77(26):1235-41. PubMed ID: 3088491
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal gammopathy of undetermined significance: an update for nephrologists.
Parry HM; Pratt G; Hutchison CA
Adv Chronic Kidney Dis; 2012 Sep; 19(5):291-6. PubMed ID: 22920639
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA
Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia.
Kyle RA; Therneau TM; Dispenzieri A; Kumar S; Benson JT; Larson DR; Melton LJ; Rajkumar SV
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):184-6. PubMed ID: 23490989
[TBL] [Abstract][Full Text] [Related]
18. Light-chain MGUS: implications for clinical practice.
van Rhee F
Lancet; 2010 May; 375(9727):1670-1. PubMed ID: 20472153
[No Abstract] [Full Text] [Related]
19. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders.
Morra E; Cesana C; Klersy C; Barbarano L; Varettoni M; Cavanna L; Canesi B; Tresoldi E; Miqueleiz S; Bernuzzi P; Nosari AM; Lazzarino M
Leukemia; 2004 Sep; 18(9):1512-7. PubMed ID: 15322559
[TBL] [Abstract][Full Text] [Related]
20. Classifying ultra-high risk smoldering myeloma.
Waxman AJ; Mick R; Garfall AL; Cohen A; Vogl DT; Stadtmauer EA; Weiss BM
Leukemia; 2015 Mar; 29(3):751-3. PubMed ID: 25371175
[No Abstract] [Full Text] [Related]
[Next] [New Search]
